Printer Friendly
The Free Library
14,716,498 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Kobayashi Pharmaceutical Introduces New OTC Anemia Treatment.


Tokyo, Japan, Mar 17, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - Kobayashi Pharmaceutical began the nationwide distributing Fai-chi, an over-the-counter (OTC OTC

See: Over-the-counter.


OTC

See over-the-counter market (OTC).
) drug for treating anemia, on March 16.

Fai-chi, which contains iron, folic acid folic acid: see coenzyme; vitamin.
folic acid
 or folate

Organic compound essential to animal growth and health and needed by bacteria as a growth factor.
 and vitamin B vitamin B
n.
1. Vitamin B complex.

2. A member of the vitamin B complex, especially thiamine.



vitamin B, vitamin B complex

a group of water-soluble substances described separately.
12 as active ingredients, helps increase hemoglobin levels and in doing so, alleviates anemic conditions. It is beneficial if taken once a day.

The product comes in three sizes: a 30-tablet bottle, a 60-tablet bottle and a 120-tablet bottle. They are priced at 900 yen (US $7.60), 1,500 yen (US $12.60) and 2,700 yen (US $22.80), respectively.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Mar 17, 2006
Words:103
Previous Article:Kobayashi Pharmaceutical Launches New Adult Acne Remedy 'Fukidia'.
Next Article:Eisai Announces Results of Overseas Clinical Trials of Donepezil in Treating Vascular Dementia.



Related Articles
Kobayashi Pharmaceutical Announces Results for the Third Quarter Ended December 31, 2005.
Medical maverick Tsuneo Kobayashi: a forerunner of cancer treatment and prevention.
Takeda Pharmaceutical, Affymax Conclude Licensing Agreement for Hematide, Renal/Malignant Anemia Treatment Agent.
Kobayashi Pharmaceutical Launches New Adult Acne Remedy 'Fukidia'.
Kobayashi Pharmaceutical Reports Financial Results for the Year Ended March 31, 2006.
Kobayashi Pharmaceutical Reports Financial Results for the First Quarter Ended June 30, 2006.
Kobayashi Pharmaceutical Reports Financial Results for the First Half Ended Sept. 30, 2006.
Kobayashi Pharmaceutical Announces Results for the Third Quarter Ended December 31, 2006.
Kirin's NESP(R) Long-Acting Erythropoiesis Stimulating Agent Injection Syringe Receives Approval in Japan.
Kobayashi Pharmaceutical Reports Financial Results for the Year Ended March 31, 2007.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles